{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-013176","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.341735+00:00","generated_at":"2026-05-20T03:17:43.863938+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025","bullets":["Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.","Trial evaluates THIO sequenced with CPI cemiplimab in advanced NSCLC patients after 2+ prior therapies.","Corporate presentation posted to MAIA website on June 2, 2025, filed as Exhibit 99.2.","Poster available on MAIA's website from June 2, 2025 onward."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-013176","json":"https://secwatch.observer/filing/0001641172-25-013176.json","markdown":"https://secwatch.observer/filing/0001641172-25-013176.md","text":"https://secwatch.observer/filing/0001641172-25-013176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225013176/0001641172-25-013176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225013176/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:17:43.863938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}